1,170
Participants
Start Date
August 1, 2019
Primary Completion Date
November 30, 2021
Study Completion Date
August 31, 2022
Active Comparator: Pathology
Routine treatment for bladder cancer, and surgical pathology for confirmation of patients with urothelial carcinoma.
Active Comparator: Clinical Diagnosis
Routine clinical diagnosis and treatment of benign disease of the urinary system
Active Comparator: Clinical diagnosis
Routine urine test and imaging diagnostic techniques, such as B-ultrasound.
Genetic test: AnchorDx's urine DNA methylation/somatic mutation profiling assay
A urine-based assay for the detection of urothelial carcinoma using urine DNA methylation/somatic mutation profiling analysis.
Sun Yat-sen Memorial Hospital, Sun Yat-sen University,, Guangzhou
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
OTHER
West China Hospital
OTHER
RenJi Hospital
OTHER
Tongji Hospital
OTHER
Peking University People's Hospital
OTHER
First Affiliated Hospital Xi'an Jiaotong University
OTHER
The First Affiliated Hospital with Nanjing Medical University
OTHER
Southern Medical University, China
OTHER
Nanfang Hospital, Southern Medical University
OTHER
Sichuan Cancer Hospital and Research Institute
OTHER
Affiliated Hospital & Clinical Medical College of Chengdu University
UNKNOWN
AnchorDx Medical Co., Ltd.
INDUSTRY